CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 3, April 2013
92
AFRICA
tissue plasminogen activator therapy in the 3- to 4.5-hour window :
joint outcome table analysis of the ECASS 3 trial.
Stroke
2009;
40
:
2433–2437.
17. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clini-
cally relevant number needed to harm.
Stroke
2007;
38
: 2279–2283.
18. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; on behalf of the
American Heart Association Stroke Council. Expansion of the time
window for treatment of acute ischaemic stroke with intravenous
tissue plasminogen activator: a science advisory from the American
Heart Association/American Stroke Association.
Stroke
2009;
40
:
2945–2948.
19. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F,
et al
.
A randomised trial of tenecteplase versus alteplase for acute ischaemic
stroke.
N Engl J Med
2012;
366
: 1099–1107.
20. The IST-3 collaborative group. The benefits and harms of intravenous
thrombolysis with recombinant tissue plasminogen activator within 6 h
of acute ischaemic stroke (the third international stroke trial [IST-3]): a
randomised controlled trial.
Lancet
2012;
379
: 2352–2363.
21. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C,
et
al
. Intra-arterial prourokinase for acute ischemic stroke. The PROACT
II study: a randomized controlled trial. Prolyse in Acute Cerebral
Thromboembolism.
J Am Med Assoc
1999;
282
(21): 2003–2011.
22. Khalessi AA, Natarajan SK, Orion D, Binning MJ, Siddiqui A, Levy EI,
Hopkins LN. Acute stroke intervention.
J Am Col Cardiol Cardiovasc
Interv
2011;
4
(3): 261–269.
23. Powers WJ. Thromobolysis for acute ischaemic stroke: is intra-
arterial better than intravenous? A treatment effects model.
J Stroke
Cerebrovasc Dis
2012;
21
(5): 401–403.
24. Cohen JE, Itshayek E, Moskovici S, Gomori JM, Fraifeld S, Eichel R,
Leker RR. State-of-the-art reperfusion strategies for acute ischemic
stroke.
J Clin Neurosci
2011;
18
(3): 319–323.
25. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, GobinYP,
et al
;
MERCI Trial Investigators. Safety and efficacy of mechanical embolec-
tomy in acute ischemic stroke: results of the MERCI trial.
Stroke
2005;
36
(7): 1432–1438.
26. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS,
et
al
; Multi MERCI Investigators, Frei D, Grobelny T, Hellinger F, Huddle
D, Kidwell C, Koroshetz W,
et al
. Mechanical thrombectomy for acute
ischemic stroke: final results of the Multi MERCI trial.
Stroke
2008;
39
(4): 1205–1212.
27. The penumbra pivotal stroke trial: safety and effectiveness of a new
generation of mechanical devices for clot removal in intracranial large
vessel occlusive disease. Penumbra Pivotal Stroke Trial Investigators.
Stroke
2009;
40
(8): 2761–2768.
28. Baker WL, Colby JA, Tongbram V, Talati R, Silverman IE, White CM,
et al
. Neurothrombectomy devices for the treatment of acute ischemic
stroke: state of the evidence.
Ann Intern Med
2011;
154
(4): 243–252.
29. Velat GJ, Hoh BL, Levy EI, Mocco J. Primary intracranial stenting in
acute ischemic stroke.
Curr Cardiol Rep
2010;
12
(1): 14–19.
30. Mpotsaris A, Bussmeyer M, Loehr C, Oelerich M, Buchner H, Weber
W. Mechanical thrombectomy in severe acute stroke: preliminary
results of the Solitaire stent
. J Neurol Neurosurg Psychiatry
2012;
83
(1): 117–118.
31. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST:
randomised placebo-controlled trial of early aspirin use in 20,000
patients with acute ischaemic stroke.
Lancet
1997;
349
(9066): 1641–
1649.
32. International Stroke Trial Collaborative Group. The International
Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin,
both, or neither among 19435 patients with acute ischaemic stroke.
Lancet
1997;
349
(9065): 1569–1581.
33. Halkes PH, Gray LJ, Bath PM, Diener HC, Guiraud-Chaumeil B, Yatsu
FM, Algra A. Dipyridamole plus aspirin versus aspirin alone in second-
ary prevention after TIA or stroke: a meta-analysis by risk. J
Neurol
Neurosurg Psychiatry
2008;
79
(11): 1218–1223.
34. CAPRIE Steering Committee. A randomised, blinded, trial of clopi-
dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet
1996;
348
(9038): 1329–1339.
35. Halkes PHA, van Gijn, Kappelle LJ, Koudstaal PJ, Algra A, ESPRIT
study group. Risk indicators for development of headache during dipy-
ridamole treatment after cerebral ischaemia of arterial origin. J
Neurol
Neurosurg Psychiatry
2009;
80
: 437–439
36. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste
M,
et al
; MATCH investigators. Aspirin and clopidogrel compared with
clopidogrel alone after recent ischaemic stroke or transient ischaemic
attack in high-risk patients (MATCH): randomised, double-blind,
placebo-controlled trial.
Lancet
2004;
364
(9431): 331–337.
37. Greenhalgh J, Bagust A, BolandA, Martin Saborido C, Oyee J, Blundell
M,
et al
. Clopidogrel and modified-release dipyridamole for the preven-
tion of occlusive vascular events (review of Technology Appraisal No.
90): a systematic review and economic analysis. H
ealth Technol Assess
2011;
15
(31): 1–178.
38. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with
ischaemic stroke and transient ischaemic attack to prevent recurrent
major vascular events.
Lancet Neurol
2010;
9
(3): 273–284.
39. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh
A,
et al
, RE-LY Steering Committee and Investigators. Dabigatran
versus warfarin in patients with atrial fibrillation.
N Engl J Med
2009;
361
(12): 1139–1151.
40. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W,
et al
;
ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvular
atrial fibrillation.
N Engl J Med
2011;
365
(10): 883–891.
41. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM,
Hanna M,
et al
; ARISTOTLE Committees and Investigators. Apixaban
versus warfarin in patients with atrial fibrillation.
N Engl J Med
2011;
365
(11): 981–992.
42. Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS,
Lip GY. Novel oral anticoagulants for stroke prevention in atrial fibril-
lation: focus on apixaban.
Adv Ther
2012;
29
(6): 491–507.
43. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-
analysis of efficacy and safety of new oral anticoagulants (dabigatran,
rivaroxaban, apixaban) versus warfarin in patients with atrial fibrilla-
tion
. Am J Cardiol
2012;
110
(3): 453–460.
44. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban
and apixaban for atrial fibrillation.
Thromb Haemost
2012 Jun 28;
108
(3). EPub ahead of print.
45. Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU,
Peng S,
et al
. Dabigatran versus rivaroxaban for the prevention of stroke
and systemic embolism in atrial fibrillation in Canada. Comparative
efficacy and cost-effectiveness.
Thromb Haemost
2012;
108
(4). Epub
ahead of print.
46. Baker WL, Phung OJ. Systematic review and adjusted indirect compari-
son meta-analysis of oral anticoagulants in atrial fibrillation.
Circ
Cardiovasc Qual Outcomes
2012 Aug 21. Epub ahead of print.
47. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY,
et al
; AVERROES Steering Committee and Investigators. Apixaban
versus aspirin in patients with atrial fibrillation and previous stroke
or transient ischaemic attack: a predefined subgroup analysis from
AVERROES, a randomised trial.
Lancet Neurol
2012;
11
(3): 225–231.
48. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke
prevention and carotid atherosclerosis: systematic review and up-to-
date meta-analysis.
Stroke
2004;
35
(12): 2902–2909.
49. Gaspardone A, Arca M. Atorvastatin: its clinical role in cerebrovascular
prevention.
Drugs
2007;
67
(Suppl 1): 55–62.
50. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan
SC,
et al
; American Heart Association Stroke Council, Council
on Cardiovascular Nursing, Council on Clinical Cardiology, and
Interdisciplinary Council on Quality of Care and Outcomes Research.
Guidelines for the prevention of stroke in patients with stroke or tran-
sient ischemic attack: a guideline for healthcare professionals from
the American Heart Association/American Stroke Association.
Stroke
2011;
42
(1): 227–276.
51. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ,
Marais AD. Reduction in mortality in subjects with homozygous famil-
ial hypercholesterolemia associated with advances in lipid-lowering
therapy.
Circulation
2011;
124
(20): 2202–2207.
